| A drug safety evaluation of valsartan. | |
| | |
MedLine Citation:
|
PMID: 21142805 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin receptor blockers (ARBs) as a class are generally considered safe and better tolerated than other antihypertensive drugs. The purpose of this report is to review the main data on the safety and tolerability of the second generation ARB valsartan after > 10 years since its initial approval. AREAS COVERED: We searched Medline for clinical studies published between 1997 and 2010 that involve valsartan and focus on its safety and tolerability profile. The main large-scale studies in hypertension, heart failure, post-myocardial infarction (MI) and chronic kidney disease are reviewed. EXPERT OPINION: Valsartan demonstrates to be safe and well tolerated both in monotherapy and in combination therapy of hypertension in a broad range of patients, including the elderly, children, diabetics, obese patients and patients at high cardiovascular risk. The most frequently reported adverse events (AEs) are malaise/fatigue, dizziness, headache and nausea/vomiting, whose incidence, however, is similar to that observed with placebo. Cough, a common class effect of ACE inhibitors, occurs less frequently with valsartan. When combined with hydrochlorothiazide, valsartan counteracts the adverse metabolic effects of the diuretic, whereas it reduces ankle edema formation when combined with amlodipine. In diabetic hypertensives, valsartan does not adversely affect glucose and lipid metabolism and even improves it. In post-MI patients, the rate of discontinuation due to AE, mainly hypotension, cough and increased serum creatinine, is lower in valsartan than in ACE inhibitor treated patients. Valsartan is also safe and well tolerated in patients with nephropathy although serum potassium levels need to be monitored more closely. |
| | |
Authors:
|
Roberto Fogari; Annalisa Zoppi |
Related Documents
:
|
22531525 - Primary leiomyosarcoma of epididymis. 19411805 - Serum thyroid autoantibodies in patients with idiopathic either acute or chronic urtica... 19581015 - The human leukocyte antigen class ii gene has different contributions to autoimmune typ... 2548935 - Influence of secondary cytoreduction at the time of second-look laparotomy on the survi... 2156085 - Neurologic consequences of electrical burns. 20165655 - Diagnostic values of electrocardiogram in chronic obstructive pulmonary disease (copd). |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-12-11 |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: 10 ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-02-23 Completed Date: 2011-06-20 Revised Date: 2013-05-20 |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 295-303 Citation Subset: IM |
Affiliation:
|
Clinica Medica II, Centro Ipertensione e Fisiopatologia Cardiovascolare, Department of Internal Medicine and Therapeutics, Fondazione IRCC Policlinico San Matteo, Piazzale Golgi 19, 27100 Pavia, Italy. r.fogari@unipv.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Age Factors Aged Angiotensin II Type 1 Receptor Blockers / administration & dosage, adverse effects*, therapeutic use Antihypertensive Agents / administration & dosage, adverse effects*, therapeutic use Child Drug Therapy, Combination Humans Hypertension / drug therapy Risk Factors Tetrazoles / administration & dosage, adverse effects*, therapeutic use Valine / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and re...
Next Document: Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung c...